X4 Pharmaceuticals Inc

X4 Pharmaceuticals said it entered into a senior secured term loan facility of up to $150M with K2 HealthVentures, replacing its previous loan agreement and providing the company with additional financial flexibility. The first $80M tranche was funded at closing and used to fully repay the company's previous loan, including $75M of principal and related fees, as well as associated closing costs. An additional $70M may be made available at X4's request, subject to K2HV approval and other conditions. The new facility provides a larger total borrowing capacity, a longer interest-only period and a 48-month maturity, supporting X4's corporate activities, including the potential commercial launch of mavorixafor in chronic neutropenia.

X4 Pharmaceuticals has appointed Kelly Gold to its Board of Directors effective July 1, 2026. Ms. Gold will serve as an independent director and member of the Audit Committee. She is currently the Chief Financial Officer at CAMP4 Therapeutics and brings financial leadership, capital markets expertise, and a scientific background to the board. The company stated that her experience as a public company CFO and her understanding of the biotech landscape will support X4 as it advances mavorixafor toward potential approval and commercialization.